2020 World Conference on Lung Cancer - January 28 - 31, 2021 Alex Spira, MD, PhD, FACP

Alex Spira, MD, PhD, FACP Presenting Author and Contributing author for multiple presentations for the 2020 World Conference on Lung Cancer – January 28 – 31, 2021

https://library.iaslc.org/search-speaker?search_speaker=87361

FP02 – Health Services Research/Health Economics

Event: WCLC 2020
Type: Posters (Featured)
Track: Health Services Research/Health Economics
Presentations: 1

FP02.02 – Real-World Outcomes Among Advanced Non-Small Cell Lung Cancer Patients Re-Treated with Immunotherapy in the US

00:00 – 00:00 | Presenting Author(s): Alex I. Spira

OA03 – Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC

Event: WCLC 2020
Type: Oral
Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
Presentations: 1

OA03.03 – Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study (ID 3407)

10:30 – 11:30 | Presenting Author(s): Alex I. Spira

1/29/2021, 10:30 – 11:30, Scientific Program Auditorium

OA04 – New Data from Rare EGFR Alterations

Event: WCLC 2020
Type: Oral
Track: Targeted Therapy – Clinically Focused
Presentations: 1

OA04.04 – Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer (ID 3031)

11:45 – 12:45 | Author(s): Alex I. Spira

1/29/2021, 11:45 – 12:45, Scientific Program Auditorium

P01 – Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics

Event: WCLC 2020
Type: Posters
Track: Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics
Presentations: 1

P01.06 – CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients With Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase

00:00 – 00:00 | Author(s): Alex I. Spira

1/28/2021, 00:00 – 00:00, ePoster Hall

P77 – Immunotherapy (Phase II/III Trials) – Combining Different Immunotherapeutic Approaches

Event: WCLC 2020
Type: Posters
Track: Immunotherapy (Phase II/III Trials)
Presentations: 1

77.02 – Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC

00:00 – 00:00 | Author(s): Alex I. Spira

1/28/2021, 00:00 – 00:00, ePoster Hall

P90 – Targeted Therapy – Clinically Focused – Misc. Topics

Event: WCLC 2020
Type: Posters
Track: Targeted Therapy – Clinically Focused
Presentations: 1

P90.03 – A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (ID 2968)

00:00 – 00:00 | Presenting Author(s): Alex I. Spira

PS01 – Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)

Event: WCLC 2020
Type: Plenary
Track: N.A.

Presentations: 1

PS01.07 – CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer (ID 3037)

07:00 – 09:00 | Author(s): Alex I. Spira

PS02 – Presidential Symposium (Re-Broadcast) (Japanese, Mandarin, Spanish Translation Available) (ID 275)

Event: WCLC 2020
Type: Plenary
Track: N.A.
Presentations: 1

PS02.07 – CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer (ID 4290)

18:00 – 20:00 | Author(s): Alex I. Spira

2020 World Conference on Lung Cancer - January 28 - 31, 2021 Alex Spira, MD, PhD, FACP

Virginia Cancer Specialists Practice Blog

January 28, 2021

Alex Spira, MD, PhD, FACP Presenting Author and Contributing author for multiple presentations for the 2020 World Conference on Lung Cancer – January 28 – 31, 2021

FP02 – Health Services Research/Health Economics

FP02.02 – Real-World Outcomes Among Advanced Non-Small Cell Lung Cancer Patients Re-Treated with Immunotherapy in the US

OA03 – Promising Antibody-Drug Conjugate and Cytotoxic Therapy in NSCLC

OA03.03 – Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in Patients With Advanced NSCLC: Updated Results of TROPION-PanTumor01 Phase 1 Study (ID 3407)

OA04 – New Data from Rare EGFR Alterations

OA04.04 – Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer (ID 3031)

P01 – Antibody Drug Conjugates, Novel Therapeutics and Cytotoxics

P01.06 – CX-2029, a Probody Drug Conjugate Targeting CD71 in Patients With Selected Tumor Types: PROCLAIM-CX-2029 Dose Expansion Phase

P77 – Immunotherapy (Phase II/III Trials) – Combining Different Immunotherapeutic Approaches

77.02 – Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC

P90 – Targeted Therapy – Clinically Focused – Misc. Topics

P90.03 – A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (ID 2968)

PS01 – Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)

PS01.07 – CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer (ID 3037)

PS02 – Presidential Symposium (Re-Broadcast) (Japanese, Mandarin, Spanish Translation Available) (ID 275)

PS02.07 – CodeBreaK 100: Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutated Non-small Cell Lung Cancer (ID 4290)

Recent Posts

26 Physicians from Virginia Cancer Specialists Named to Washingtonian Magazine’s Top Doctors List 2024

January 6, 2025

Practice Announcement: 1/5/25, 8:45 PM.: Inclement Weather Alert

January 5, 2025

Virginia Cancer Specialists Earns Full Accreditation from NCODA’s Center of Excellence Medically Integrated Pharmacy Program

December 3, 2024

The US Oncology Network Launches Innovative Program to Foster Retention of New Oncology Nurses

November 21, 2024

Virginia Cancer Specialists Initiates First Radiopharmaceutical Clinical Trial of Its Kind, Promising New Hope for Patients

November 13, 2024

Award Winning Physicians